Lundbeckfond Invest launches exchange offer for H. Lundbeck A-shares
Lundbeckfond Invest A/S, the largest shareholder in H. Lundbeck A/S, has launched a voluntary exchange offer for the company's A-shares. The offer is directed at eligible shareholders.
Lundbeckfond Invest A/S has initiated a voluntary exchange offer for the A-shares of H. Lundbeck A/S. Lundbeckfond Invest serves as H. Lundbeck's largest shareholder and is a wholly-owned subsidiary of the Lundbeck Foundation.
The offer is targeted towards specific shareholders, with the objective of increasing Lundbeckfond Invest's ownership stake in H. Lundbeck. Detailed terms and conditions, along with the timeline, will be communicated to shareholders in due course.
Further details regarding the transaction and the offer's objectives are expected to be disclosed in the coming weeks. The company anticipates that the offer will contribute to clarifying ownership structures and support H. Lundbeck's long-term strategic direction.
H. Lundbeck is a global pharmaceutical company specializing in treatments for central nervous system disorders. Its portfolio includes medications for conditions such as depression, schizophrenia, and Alzheimer's disease.